DOCSLIB.ORG

Trendsrx®Drug Pipeline & News

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trendsrx®Drug Pipeline & News TrendsRx® June 2009 TrendsRx®Drug Pipeline & News Volume 5, Number 6 Pipeline Highlights: April 27, 2009 – May 29, 2009 and Recent Selected Health Care News Highlights Selected Generic Product Approvals/Launches1,2* azelastine Dosage Form; Strength Spray, nasal; 125 mcg/spray hydrochloride Approval Date† April 30, 2009 (Astelin®) Anticipated Launch Date‡ TBD Comments The reference brand is used for the treatment of the symptoms of seasonal allergic rhinitis (patients 5 years of age and older) and nonallergic vasomotor rhinitis (patients 12 years of age and older). This product is therapeutically equivalent to its reference brand and will be available from a single generics manufacturer. mycophenolate Dosage Forms; Strengths Tablet, oral; 500 mg mofetil Capsule, oral; 250 mg (Cellcept®) Approval Date† May 4, 2009 Launch Date‡ May 4, 2009 Comments This product is AB-rated and will be available from multiple generics manufacturers. Recent Product Launches1,2* Savella™ Dosage Form; Strengths Tablet, oral; 12.5 mg, 25 mg, 50 mg and 100 mg (milnacipran) Indication For the management of fibromyalgia Launch Date‡ April 28, 2009 Cypress Bioscience, Inc./Forest Laboratories, Inc. Ryzolt™ (tramadol Dosage Form; Strengths Tablet, oral, extended-release; 100 mg, 200 mg and 300 mg. extended release) Indication For the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time Purdue Pharma Launch Date‡ May 7, 2009 Recent Biologic License Application (BLA) Approvals1,2* Simponi™ Dosage Form; Strength Injection, subcutaneous; 50 mg/0.5 mL in a single dose prefilled SmartJect autoinjector and 50 mg/0.5 mL in a single (golimumab) dose prefilled syringe Indications For the treatment of moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; active psoriatic arthritis in adults, alone or in combination with methotrexate; and active ankylosing spondylitis in adults Centocor Ortho Approval Date April 24, 2009 Biotech LLC Launch Date‡ April 30, 2009 www.caremark.com Recent New Drug Application (NDA) Approvals1,2* Dysport® Dosage Form; Strengths Injection, intramuscular; 250 units/0.5 mL and 500 units/mL (botulinum toxin Indications For the treatment of cervical dystonia and for the temporary improvement in the appearance of moderate to severe type A) glabellar lines associated with procerus and corrugator muscle activity in adult patients < 65 years of age Approval Date April 30, 2009 ‡ Ipsen Inc./Medicis Launch Date Second and third quarter 2009 Pharmaceutical Comments Ipsen will market Dysport for cervical dystonia with an anticipated launch in the second half of 2009. Corp. Medicis will market Dysport for glabellar lines with an anticipated launch in Q2 2009. Exforge® HCT Dosage Form; Strengths Tablet, oral; 5mg/160mg/12.5mg, 10mg/160mg/12.5mg, 5mg/160mg/25mg and 10mg/320mg/25mg (amlodipine/ Indication For the treatment of hypertension valsartan/ Approval Date April 30, 2009 hydrochlorothiazide) Anticipated Launch Date‡ May 2009 Novartis Pharmaceuticals Corporation Creon® Dosage Form; Strengths Capsule, oral, delayed-release; 6,000 USP units of lipase, 19,000 USP units of protease, 30,000 USP units of amylase; (pancrelipase) 12,000 USP units of lipase, 38,000 USP units of protease, 60,000 USP units of amylase; 24,000 USP units of lipase, 76,000 USP units of protease, 120,000 USP units of amylase Indication For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions Solvay Approval Date April 30, 2009 Pharmaceuticals Anticipated Launch Date‡ Third quarter 2009 Cycloset® Dosage Form; Strength Tablet, oral; 0.8 mg (bromocriptine Indication Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus mesylate) Approval Date May 5, 2009 VeroScience/S2 Anticipated Launch Date‡ 2010 Therapeutics Fanapt™ Dosage Form; Strengths Tablet, oral; 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg (iloperidone) Indication For the acute treatment of schizophrenia in adults Vanda Approval Date May 6, 2009 Pharmaceuticals Anticipated Launch Date‡ Third quarter 2009 Cetraxal® Otic Dosage Form; Strength Solution, otic; 0.2% (ciprofloxacin) Indication For the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus Laboratorios Approval Date May 1, 2009 SALVAT Anticipated Launch Date‡ Second quarter 2009 ACTOplus met® XR Dosage Form; Strengths Tablet, oral, extended-release; 15 mg/1000 mg and 30mg/1000 mg (pioglitazone/ Indication Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are metformin already treated with pioglitazone and metformin or who have inadequate glycemic control on pioglitazone alone or extended release) metformin alone Approval Date May 12, 2009 Takeda Anticipated Launch Date‡ Fourth quarter 2009 Pharmaceuticals Lamictal® ODT™ Dosage Form; Strengths Tablet, orally disintegrating; 25 mg, 50 mg, 100 mg and 200 mg (lamotrigine) Indications Indicated for the long-term treatment of bipolar I disorder in people 18 years or older who have been treated with other medicine; as adjunctive therapy to treat certain types of seizures (partial seizures, primary generalized tonic-clonic seizures, generalized seizures of Lennox-Gastaut syndrome) in people two years or older or alone when changing from other medicines used to treat partial seizures in people 16 years or older. Approval Date May 8, 2009 GlaxoSmithKline Anticipated Launch Date‡ July 2009 Samsca™ Dosage Form; Strengths Tablet, oral; 15 mg, 30 mg and 60 mg (tolvaptan) Indication Indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone. Otsuka America Approval Date May 19, 2009 Pharmaceutical Anticipated Launch Date‡ Second quarter 2009 Adcirca™ (tadalafil) Dosage Form; Strength Tablet, oral; 20 mg Indication Indicated for the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability. United Approval Date May 22, 2009 Therapeutics Anticipated Launch Date‡ August 2009 Recent Supplemental New Drug Application (sNDA) Approvals1,2* Revatio™ Dosage Form Tablet, oral (sildenafil citrate) Indication To delay clinical worsening in patients with pulmonary arterial hypertension (WHO Group I) Approval Date May 7, 2009 Comments This is a new indication for an already approved product. Pfizer This product will be available through the CVS Caremark Specialty Pharmacy Services Network. Azor® (amlodipine Dosage Form Tablet, oral besylate/ Indication For the treatment of hypertension as initial therapy in patients likely to need multiple antihypertensive agents to achieve olmesartan their blood pressure goals medoxomil) Approval Date May 11, 2009 Daiichi Sankyo Co., Comments This is a new indication for an already approved product. Ltd. Risperdal® Consta® Dosage Form Injection, intramuscular (risperidone) Indication For use as adjunctive therapy with lithium or valproate for the maintenance treatment of bipolar I disorder; and as monotherapy for the maintenance treatment of bipolar I disorder Ortho-McNeil Approval Date May 15, 2009 Janssen Comments This is a new indication for an already approved product. Prograf® Dosage Forms Capsule, oral; and Injection, intravenous (tacrolimus) Indication For the prophylaxis of organ rejection in kidney transplant patients in combination with mycophenolate mofetil Approval Date May 19, 2009 Astellas Pharma Comments This is a new indication for an already approved product. Recent Supplemental Biologic License Application (sBLA) Approvals1,2* Avastin® Dosage Form Injection, intravenous (bevacizumab) Indication For the treatment of glioblastoma, as a single agent for patients with progressive disease following prior therapy Roche Approval Date May 5, 2009 Laboratories/ Comments This is a new indication for an already approved product. Genentech, Inc. This product will be available through the CVS Caremark Specialty Pharmacy Services Network. Cimzia® Dosage Form Injection, subcutaneous (certolizumab Indication For the treatment of adults with moderately to severely active rheumatoid arthritis pegol) Approval Date May 13, 2009 UCB Comments This is a new indication for an already approved product. Pharmaceuticals This product will be available through the CVS Caremark Specialty Pharmacy Services Network. Inc. * Adapted from RxPipeline Services Week In Review. For more information contact: [email protected]<mailto:[email protected]> † The Approval Date is established by the FDA but does not necessarily mean a generic product is available as of that date or that such product is available. ‡ A launch date/anticipated launch date may not reflect the actual availability of this medication. Due to circumstances beyond the control of CVS Caremark, information related to prospective medication launch dates is subject to change without notice. This information should not be solely relied upon for decision-making purposes. www.caremark.com News Medication Safety Information regarding selected medication safety issues can be found on the CVS Caremark Web site at www.caremark.com > Health Professional Services > Drug Safety Alerts. Additional Labeling for Over-the-Counter
Load more

Recommended publications
  • An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: a Review
    Muthadi Radhika Reddy /J. Pharm. Sci. & Res. Vol. 12(7), 2020, 925-940 An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review Muthadi Radhika Reddy1* 1School of pharmacy, Gurunanak Institute of Technical Campus, Hyderabad, Telangana, India and Department of Pharmacy, Gandhi Institute of Technology and Management University, Vizag, Andhra Pradesh, India INTRODUCTION 2. Useful in situations where rapid onset of action Fast dissolving drug delivery systems were first developed required such as in motion sickness, allergic attack, in the late 1970s as an alternative to conventional dosage coughing or asthma forms. These systems consist of solid dosage forms that 3. Has wide range of applications in pharmaceuticals, Rx disintegrate and dissolve quickly in the oral cavity without Prescriptions and OTC medications for treating pain, the need of water [1]. Fast dissolving drug delivery cough/cold, gastro-esophageal reflux disease,erectile systems include orally disintegrating tablets (ODTs) and dysfunction, sleep disorders, dietary supplements, etc oral thin films (OTFs). The Centre for Drug Evaluation [4] and Research (CDER) defines ODTs as,“a solid dosage 4. No water is required for the administration and hence form containing medicinal substances which disintegrates suitable during travelling rapidly, usually within a matter of seconds, when placed 5. Some drugs are absorbed from the mouth, pharynx upon the tongue” [2]. USFDA defines OTFs as, “a thin, and esophagus as the saliva passes down into the flexible, non-friable polymeric film strip containing one or stomach, enhancing bioavailability of drugs more dispersed active pharmaceutical ingredients which is 6. May offer improved bioavailability for poorly water intended to be placed on the tongue for rapid soluble drugs by offering large surface area as it disintegration or dissolution in the saliva prior to disintegrates and dissolves rapidly swallowing for delivery into the gastrointestinal tract” [3].
    [Show full text]
  • Comprehensive Review on Herbal Toothpaste
    Annals of R.S.C.B., ISSN:1583-6258, Vol. 25, Issue 4, 2021, Pages. 9509 - 9518 Received 05 March 2021; Accepted 01 April 2021. Comprehensive Review on Herbal Toothpaste Divya S1, Dr. J Suresh1*, Dr. S. Meenakshi 2 1. Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru-570015 2.Department of Prosthodontics, JSS Dental College, JSS Academy of Higher Education &Research, Mysuru-570015 Corresponding author Dr. J. Suresh Professor Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru-570015 Email: [email protected] Mobile No: 9480197611 ABSTRACT Herbal products for general as well as for oral health care have gained prominence around worldwide. People who aspire towards the use of herbal products often consider these products are relatively safer than products containing synthetic ingredients. Based on increased usage of herbal cosmetics we tried to make a comprehensive review on herbal toothpaste that helps to maintain a proper oral hygiene and free from periodontal disorder, reduce stain, gingivitis, calculus and caries. The present review gives basic information regarding antimicrobial potential of various herbs, formulationexcipients, that can be used in preparation of toothpaste. Key Words: Herbal toothpaste, Anti-microbial screening, Periodontal disorder, Gingivitis, calculus, Dental caries. INTRODUCTION In developing countries, the intensity of infections caused by certain pathogenic micro- organisms that may leads to mortality as well as morbidity in immune-suppressant patients [1]. Multiple abrasives, scent, green lead was used to remove the stain from teeth until mid- 19thcentury. In Medieval period rock salt, fine sand were the key ingredients used by Arabs for tooth cleaning.In the period 1950 AD, Dr.
    [Show full text]
  • Chapter 1 Controlling Drug Delivery
    chapter 1 Controlling drug delivery Overview In this chapter we will: & differentiate drug delivery systems according to their physical state & differentiate drug delivery systems according to their route of administration & differentiate drug delivery systems according to their type of drug release & discuss drug transport across epithelial barriers. Introduction KeyPoints & Continued developments in Pharmacotherapy can be defined as the treatment chemistry, molecular biology and prevention of illness and disease by means of and genomics support the drugs of chemical or biological origin. It ranks discovery and developments among the most important methods of medical of new drugs and new drug treatment, together with surgery, physical targets. & treatment, radiation and psychotherapy. There The drug delivery system are many success stories concerning the use of employed can control the pharmacological action of a drugs and vaccines in the treatment, prevention drug, influencing its and in some cases even eradication of diseases pharmacokinetic and (e.g. smallpox, which is currently the only subsequent therapeutic human infectious disease completely profile. eradicated). Although it is almost impossible to estimate the exact extent of the impact of pharmacotherapy on human health, there can be no doubt that pharmacotherapy, together with improved sanitation, better diet and better housing, has improved people’s health, life expectancy and quality of life. Tip Unprecedented developments in genomics Combinatorial chemistry is a way to and molecular biology today offer a plethora of build a variety of structurally related new drug targets. The use of modern chemical drug compounds rapidly and synthetic methods (such as combinatorial systematically. These are assembled chemistry) enables the syntheses of a large from a range of molecular entities number of new drug candidates in shorter times which are put together in different ‘ ’ than ever before.
    [Show full text]
  • WO 2010/044736 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 April 2010 (22.04.2010) WO 2010/044736 Al (51) International Patent Classification: (74) Agents: Bratt, Henrik et al; Jarnvagsgatan 10 A, S-251 A61K 9/24 (2006.01) A61P 25/34 (2006.01) 10 Helsingborg (SE). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/SE2009/05 1163 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) Date: International Filing CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 13 October 2009 (13.10.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 0802 189-1 14 October 2008 (14.10.2008) SE SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): McNeil AB [SE/SE]; Box 941, S-25 1 09 Helsingborg (SE). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (75) Inventors/Applicants (for US only): LINDELL, Katari- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, na [SE/SE]; Skarhult 1325, S-241 93 Eslδv (SE).
    [Show full text]
  • Dosage Form Description CODE
    Dosage Form Description CODE DOSAGE_FORM DOSAGE_FORM DESCRIPTION AERO Aerosol AEPB Aerosol Powder, Breath Activated AERB Aerosol, Breath Activated AERP Aerosol, Powder AERS Aerosol, Solution AUIJ Auto-injector AJKT Auto-injector Kit BAR Bar BEAD Beads CAPS Capsule CAPA Capsule Abuse- Deterrent CPCW Capsule Chewable CPDR Capsule Delayed Release CPEP Capsule Delayed Release Particles CSDR Capsule Delayed Release Sprinkle CDPK Capsule Delayed Release Thereapy Pack C12A Capsule ER 12 Hour Abuse-Deterrent CS12 Capsule ER 12 Hour Sprinkle C2PK Capsule ER 12 Hour Therapy Pack C24A Capsule ER 24 Hour Abuse-Deterrent CS24 Capsule ER 24 Hour Sprinkle C4PK Capsule ER 24 Hour Therapy Pack CP12 Capsule Extended Release 12 Hour CP24 Capsule Extended Release 24 Hour CPEA Capsule Extended Release Abuse-Deterrent CSER Capsule Extended Release Sprinkle CEPK Capsule Extended Release Therapy Pack CPCR Capsule Extended Release* CPSP Capsule Sprinkle CPPK Capsule Therapy Pack CART Cartridge CTKT Cartridge Kit CONC Concentrate CREA Cream CRYS Crystals DEVI Device TEST Diagnostic Test DPRH Diaphragm DISK Disk ELIX Elixir EMUL Emulsion ENEM Enema EXHA Exhaler EXHL Exhaler Liquid Dosage Form Description CODE DOSAGE_FORM DOSAGE_FORM DESCRIPTION EXHP Exhaler Powder EXHS Exhaler Solution EXHU Exhaler Suspension FILM Film FLAK Flakes EXTR Fluid Extract FOAM Foam GAS Gas GEL Gel SOLG Gel Forming Solution GRAN Granules GREF Granules Effervescent GUM Gum IMPL Implant INHA Inhaler INJ Injectable INST Insert IUD Intrauterine Device JTAJ Jet-injector (Needleless) JTKT Jet-injector
    [Show full text]
  • Formulation and Evaluation of Liposomal Drug Delivery System for Doxorubicin Hydrochloride
    FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE A dissertation submitted to THE TAMILNADU Dr. M.G.R.MEDICAL UNIVERSITY, CHENNAI. In partial fulfillment of the requirements for the award of degree of MASTER OF PHARMACY IN PHARMACEUTICS BY REG.NO: 26091390 Under the Guidance of Prof. S.P.SENTHIL, M.Pharm., ( Ph.D.,) OCTOBER -2011 THE ERODE COLLEGE OF PHARMACY AND RESEARCH INSTITUTE ERODE -638112, TAMILNADU DEDICATED TO My Beloved Family, Teachers & Friends CERTIFICATES The Erode College Of Pharmacy and Research Institute Prof.S.P.SENTHIL, M.Pharm.,( Ph.D.,) Department of pharmaceutics, Perundurai Main Road, Veppampalayam, Erode-638112, India. e-mail : [email protected] CERTIFICATE This is to certify that the investigation in this thesis entitled “FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE” submitted to The Tamilnadu Dr. M.G.R. Medical University Chennai. For partial fulfillment of the award of degree of Master of pharmacy in Pharmaceutics was carried out by Reg. No: 26091390 in the department of pharmaceutics, The Erode College of pharmacy, Erode, under my guidance and supervision This work is original and has not been submitted in part or full to any other degree or diploma of this or any other university. Place: Erode Prof. S.P.SENTHIL, M.Pharm.,(Ph.D.,) Date: The Erode College Of Pharmacy and Research Institute Dr.V.Ganesan, M.Pharm., Ph.D., Professor and HOD of Pharmaceutics, Perundurai Main Road, Veppampalayam, Erode-638112, India. CERTIFICATE This is to certify that the investigation in this thesis entitled “FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE ” submitted to the Tamil Nadu Dr.
    [Show full text]
  • Medicinal Cannabis Dosage Forms in California an Overview of Cannabis Dosage Forms
    Mica Gross President Sante Botanica / COO MDBioLogics Medicinal Cannabis Dosage Forms in California An Overview of Cannabis Dosage Forms Forms of dosage are the specific vehicles by which cannabis, or cannabinoids, are delivered into the body. Cannabis (drug-containing plant) —> The “form” in which THC and other cannabinoids Extracted Oil (drug substance) —> are administered determines how they moves and Delivery / Intake (drug product) works medicinally inside the body: ie the pharmacokinetics of cannabis. Both the plant material and the oils yielded through the extraction process influence the performance of the different forms of intake, which each have a particular set of benefits. An Overview of Cannabis Dosage Forms The medicinal effect experienced by the end- user is a function of the quality of the raw material – the cannabinoid and terpene profile of the cannabis – and of the derived oil yielded during extraction. The goal is to preserve the fidelity of the volatile medicinal compounds – such as the cannabinoids, terpenes, and flavonoids – throughout the entire chain of custody so that the therapeutic effect is intact and the dose is delivered in the most efficacious means possible. An Overview of Cannabis Dosage Forms Each form of intake is formulated to take advantage of the pharmacokinetic pathways as effectively as possible in delivering a therapeutic dose of cannabinoids (e.g. THC or CBD). An Overview of Cannabis Dosage Forms Important factors when considering each form of intake: • Bioavailability – the fraction of the administered
    [Show full text]
  • Aqueous Emulsion Coating for Pharmaceutical Dosage Form
    Europaisches Patentamt 0 347 024 3> European Patent Office J) Publication number: Dffice europeen des brevets 3) EUROPEAN PATENT APPLICATION © Application number: 89303290.4 © Int. CI.4: A61K 9/32 , A61K 9/36 , A61K 9/22 © Date of filing: 04.04.89 The title of the invention has been amended © Applicant: ALZA CORPORATION (Guidelines for Examination in the EPO, A-lll, 950 Page Mill Road P.O. Box 10950 7.3). Palo Alto California 94303-0802(US) © Inventor: Wong, Patrick S.-L. © Priority: 21.04.88 US 184478 2030 Cornell Street Palo Alto California 94306(US) © Date of publication of application: Inventor: Theeuwes, Felix 20.12.89 Bulletin 89/51 1634 Fallen Leaf Lane Los Altos California 94022(US) © Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE © Representative: Evans, David Charles et al F.J. CLEVELAND & COMPANY 40-43, Chancery Lane London, WC2A UQ(GB) © Aqueous emulsion coating for pharmaceutical dosage form. © A dosage form is disclosed comprising a cured emulsion coat that surrounds a drug. The emulsion comprises a lower alkyl acrylate-lower alkyl methacrylate copolymer and ethyl cellulose. The emulsion optionally comprises a hydrophilic poly- mer. eg < CM CO CL LU Xerox Copy Centre 1 EP 0 347 024 A2 2 AQUEOUS EMULSION FOR PHARMACEUTICAL DOSAGE FORM This invention pertains to a pharmaceutical final dosage form. dosage form comprising an aqueous emulsion coat It will be appreciated by those skilled in the and to an aqueous emulsion coat. drug dispensing art that if a coating is provided that is substantially free of organic solvents when coat- 5 ing drugs, drug granules, drug powders, drug dis- BACKGROUND OF THE INVENTION pensers, and the like, such a coating would have an immediate positive value and, concomitantly, represent an advancement in the drug coating art.
    [Show full text]
  • Draft Guidance on Nicotine Active Ingredient
    Contains Nonbinding Recommendations Draft Guidance on Nicotine This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Nicotine Dosage Form; Route: Film, extended release; transdermal Recommended Studies: Three studies 1. Type of study: Bioequivalence (BE) study with pharmacokinetic (PK) endpoints Design: Single-dose, two-treatment, two-period crossover in vivo Strength: 21 mg/24 hr Subjects: Males and non-pregnant, non-lactating females, smokers Additional comments: In this document, this dosage form is referred to as a transdermal delivery system (TDS) and includes products that may be described elsewhere or known as patches or extended release films. Unless otherwise justified, the nicotine TDS should be applied to the same anatomical site on all subjects, selected from among those recommended for dosing in the approved labeling for the reference listed drug (RLD) product, and worn for 24 hours. Applicants should randomize subjects to receive either the test or RLD product in a given study period. When possible, the TDS administered in the second study period should be applied to the same anatomical site as in the first study period, but on the contralateral side of the body. Contact of the TDS with the skin is essential for the in vivo performance of the TDS, and the PK may be altered when a TDS loses its adherence to the skin.
    [Show full text]
  • Dosage Form FDA Data Element Number
    Home Drugs Development & Approval Process (Drugs) Forms & Submission Requirements Electronic Submissions to CDER Data Standards Manual (monographs) Drugs Dosage Form FDA Data Element Number. None. CDER Data Element Number. C-DRG-00201 Data Element Name. Dosage Form. Data Element OID: 2.16.840.1.113883.3.26.1.1.2 Data Element NCI Concept ID: C42636 Version Number. 008 Description. This standard provides for all drug dosage forms. The granularity of data often requires that more specific dosage form terms be stored in automated databases than are represented in publications. These dosage form terms are available not only for use in databases that track approved drug products, but also for drug products such as: those that have not been approved, investigational drug products, homeopathic drug products, biologic products, veterinary drug products, and bulk drug products. A ‘use restrictions’ column is being added to help identify where a particular dosage form set or subset should be used (a=CDER Databases, b=NDC Directory, c=Orange Book). The definitions for Lotion, Cream, Ointment, and Paste were revised on June 21, 2006 to include information that would assist the user in differentiating between these dosage forms. These changes were the result of discussions during an FDA Advisory Committee with an open public forum, scientific studies that were published in refereed pharmaceutical journals, and internal discussions by Agency personnel, including the usual adherence to the criteria that are specified in MaPP 7600.4. A 1999 Food and Drug Administration Draft Guidance for Industry states: "A dosage form is the way of identifying the drug in its physical form.
    [Show full text]
  • Thin Films As an Emerging Platform for Drug Delivery
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector asian journal of pharmaceutical sciences 11 (2016) 559–574 HOSTED BY Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/ajps Review Thin films as an emerging platform for drug delivery Sandeep Karki a,1, Hyeongmin Kim a,b,c,1, Seon-Jeong Na a, Dohyun Shin a,c, Kanghee Jo a,c, Jaehwi Lee a,b,c,* a Pharmaceutical Formulation Design Laboratory, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea b Bio-Integration Research Center for Nutra-Pharmaceutical Epigenetics, Chung-Ang University, Seoul 06974, Republic of Korea c Center for Metareceptome Research, Chung-Ang University, Seoul 06974, Republic of Korea ARTICLE INFO ABSTRACT Article history: Pharmaceutical scientists throughout the world are trying to explore thin films as a novel Received 21 April 2016 drug delivery tool. Thin films have been identified as an alternative approach to conven- Accepted 12 May 2016 tional dosage forms. The thin films are considered to be convenient to swallow, self- Available online 6 June 2016 administrable, and fast dissolving dosage form, all of which make it as a versatile platform for drug delivery. This delivery system has been used for both systemic and local action via Keywords: several routes such as oral, buccal, sublingual, ocular, and transdermal routes. The design Thin film of efficient thin films requires a comprehensive knowledge of the pharmacological and phar- Film-forming polymer maceutical properties of drugs and polymers along with an appropriate selection of Mechanical properties manufacturing processes.
    [Show full text]
  • API & Dosage Form Development
    API and Dosage Development W I T H D A LT O N Peter Pekos [ C O M P A N Y V I S I O N ] "To make the impossible possible. Dalton Pharma Services uses its scientific and pharmaceutical expertise to bring customer ideas to life. We develop their new drug products, optimize the synthesis of therapeutic candidates, and manufacture them at the highest level of quality." [ S E R V I C E S ] Contract Research Custom Synthesis Medicinal and Flow Chemistry API Process Development Formulation Development cGMP API Manufacturing cGMP Sterile Filling Analytical and Microbiology Services FDA inspected, HC approved, & MRA with EMA API Form Development API Definition Active pharmaceutical ingredient (API) – the substance(s) in pharmaceutical drugs that is/are responsible for the beneficial health effects experienced by consumers. (1) API Selection Key factors that drive API selection (2): Crystallinity: Influences the dissolution rate and transport characteristics of the drug (3) Polymorphism: The ability of a drug substance to Solubility: take on more than one form/ The ability of a solute to dissolve in crystalline phase. Influences drug solvent. Influences desired dissolution and drug stability (i.e., concentration and drug premature degradation) (4) absorption (6) Density: Influences flow properties and Stability: compressibility (5) Influenced by moisture, excipients, temperature, pH, oxygen, light (7) Particle size distribution: Influences the ability of the drug to Density: cross blood barriers, enter cells, Influences flow properties and and absorbed by the human body compressibility (5) (2) The development stage and needs API & CTD Note: In any clinical application or new drug submission the 1) description of manufacturing (including flowcharts) is required along with 2) physiochemical characteristics (melting point, boiling point, denaturation temperature, solubility) (2.3.S.2, 2.3.S.3 and 2.3.P.3) (4) Once the API form is determined, the dosage form must be selected.
    [Show full text]